Acute Repetitive Seizures Market Size to Surpass US$ 19.49 Bn by 2032

The global acute repetitive seizures market size surpassed USD 0.52 billion in 2022, and it is expected to hit around USD 19.49 billion by 2032, poised to grow at a CAGR of 44.2% from 2023 to 2032.

Acute Repetitive Seizures Market Size 2023 to 2032

Acute repetitive seizures (ARS), status epilepticus, and autoimmune encephalitis are some neurologic traumas. For all these circumstances, suitable and rapid treatment may impact patient diagnosis and alleviate neuronal injury. Since past few years, there has been massive development in terms of the treatment and diagnosis of epilepsy, still in this context very smallemphasis has been given to acute repetitive seizures. The acute repetitive seizures stance a hazard of hospital admission with a mortality threat and status epilepticus, which underlines the necessity for the initial prophecy of a clinical course.

Get the Sample

Prolonged seizures and acute repetitive seizures are considered as a neurological emergency and treatment must be rapid in such traumas. The principalaim of therapy are cessation of the seizure and deterrence of recurrence. There are numerous routes of drug administration, among all, nasal route is the most favored over others, like rectal, parenteral and buccal. The buccal route is chosen by parents and caregivers for kidsaffected with pediatric seizures subsequently medication can be directed even outside the hospital.The usage of conventional intravenous agents including phenobarbital, phenytoin, lorazepam and diazepam is well recognized in the first-line treatment of acute seizures. Nevertheless, adverse effects and the time to onset of consequence often dictate the choice amid older anticonvulsants.

Growth Factors

Increase in the number of clinical trials, a rise in emphasis on the introduction of new therapies, and the rise in requirement for nasal sprays for the treatment of epilepsy are the foremost reason influencing the development of acute repetitive seizures market across the globe. Furthermore, an intensification in the amount of supervisory approvals and promising drugs in the pipeline is expected to boost the growth of the acute repetitive seizures market within the prediction period. For illustration, in April 2018, UCB S.A. declared that the FDA acknowledged NDA for its nasal spray named Nayzilam (midazolam) designated for the treating seizures such as acute repetitive seizures and seizure clusters. This could result in the sanction of the drug in early 2019, make it the foremost ever medication permitted by the FDA in 17 years.

Additionally, in an effort to limit healthcare spending, governments are making incessant efforts to decrease hospital stays and on-site treatment costs by means of outpatient care models, like home healthcare and clinic. Developingnations including China are progressivelyemploying such healthcare modification, which is anticipated to push the growth of acute repetitive seizures marketplace.

Report Scope of the Acute Repetitive Seizures Market

Report Highlights Details
Market Size in 2023 USD 0.52 Billion
Market Size by 2032 USD 19.49 Billion
Growth Rate from 2023 to 2032 CAGR of 44.2%
Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product Type, Region Type
Companies Mentioned Neurelis, Inc., UCB S.A., Valeant Pharmaceuticals North America LLC, Alexza Pharmaceuticals, Others

Report Highlights

  • The market in the Asia Pacific is expected to expand at fastest CAGR during the forecast period driven by rising in awareness about the treatment of neurological disorders and increase in demand for new drug formulations for treating serious conditions in neurology
  • Europe is expected to offer substantial growth due to intensification in investment in research and development in the area of neurology, upsurge in funds obtainable by the government, and surge in demand for medications for epilepsy.
  • Germany is predicted to eye witness profitable growth during upcoming decade on account of rapid technological progressions in clinical, scientific, and medical sectors.

Regional Snapshots

North America is anticipated to hold the considerable market stake throughout the prediction period. The U.S. seized a share more than 18% in 2019of the total market revenues. As per data released by the CDC, in 2014, about 750,000 children and 4.3 million grownups in the U.S. suffered from epilepsy. Further, the total indirect and direct cost of epilepsy in this region is assessed to be approximately USD 15.5 billion yearly. Consequently, the existence of a large target populace for epilepsy drugs in this region will fuel the growth of acute repetitive seizuresand epilepsy market.

Asia Pacific is also prospective to perceive speedy development due to cumulative healthcare spending in emerging nations including China and India. A huge gap was detected in the treatment for acute repetitive seizures in Asia Pacific. Henceforth, the demand for the antiseizure drugs in these emerging countries inspires a shift in market potential from the previously drenched North American and European regions to such economies.

Read Also: Chemiluminescence Immunoassay Market Size US$ 13.74 Bn by 2032

Noteworthy players operating in the Acute Repetitive Seizures market include:

  • Neurelis, Inc.
  • UCB S.A.
  • Valeant Pharmaceuticals North America LLC
  • Alexza Pharmaceuticals
  • Others

Segments Covered in the Report

Product Outlook

  • NRL-1
  • Diastat Rectal Gel
  • USL-261
  • AZ-002
  • Others

Regional Outlook

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • South Africa
    • North Africa
    • Rest of Middle East & Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333







Leave a Reply

Your email address will not be published. Required fields are marked *